United Therapeutics Corp

$545.96
Market Cap 23.93B
ROE 19.2%
Gross Margin 82.9%
Debt/Equity 0.0
Current Ratio 4.8
Revenue QoQ -1.6%
EPS QoQ -0.1%
F-Score 4

About

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
18.59
vs median 35.07
P/B
4.05
vs median 2.20
ROE
0.19
vs median 0.09

Lower quality - review fundamentals carefully

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics